» Articles » PMID: 16639716

Physiologically Based Pharmacokinetic Modelling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions

Overview
Journal J Pharm Sci
Publisher Elsevier
Specialties Pharmacology
Pharmacy
Date 2006 Apr 28
PMID 16639716
Citations 344
Authors
Affiliations
Soon will be listed here.
Abstract

A key component of whole body physiologically based pharmacokinetic (WBPBPK) models is the tissue-to-plasma water partition coefficients (Kpu's). The predictability of Kpu values using mechanistically derived equations has been investigated for 7 very weak bases, 20 acids, 4 neutral drugs and 8 zwitterions in rat adipose, bone, brain, gut, heart, kidney, liver, lung, muscle, pancreas, skin, spleen and thymus. These equations incorporate expressions for dissolution in tissue water and, partitioning into neutral lipids and neutral phospholipids. Additionally, associations with acidic phospholipids were incorporated for zwitterions with a highly basic functionality, or extracellular proteins for the other compound classes. The affinity for these cellular constituents was determined from blood cell data or plasma protein binding, respectively. These equations assume drugs are passively distributed and that processes are nonsaturating. Resultant Kpu predictions were more accurate when compared to published equations, with 84% as opposed to 61% of the predicted values agreeing with experimental values to within a factor of 3. This improvement was largely due to the incorporation of distribution processes related to drug ionisation, an issue that is not addressed in earlier equations. Such advancements in parameter prediction will assist WBPBPK modelling, where time, cost and labour requirements greatly deter its application.

Citing Articles

Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion-The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.

Luecht U, Scholz W, Geiben A, Haen E, Hempel G Pharmaceutics. 2025; 17(2).

PMID: 40006546 PMC: 11858960. DOI: 10.3390/pharmaceutics17020179.


Application of a Physiologically Based Pharmacokinetic Approach to Predict Tenofovir Pharmacokinetics During Pregnancy.

Abduljalil K, De Sousa Mendes M, Salem F, Benaboud S, Gardner I AAPS J. 2025; 27(1):43.

PMID: 39939515 DOI: 10.1208/s12248-025-01031-y.


Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics.

Ozbey A, Meneses-Lorente G, Simmons B, McCallum S, Annaert P, Parrott N Clin Pharmacokinet. 2025; .

PMID: 39934586 DOI: 10.1007/s40262-024-01468-y.


Dosage Optimization Using Physiologically Based Pharmacokinetic Modeling for Pediatric Patients with Renal Impairment: A Case Study of Meropenem.

Rahim N, Sarfraz M, Bello A, Naqvi S AAPS PharmSciTech. 2025; 26(1):38.

PMID: 39821536 DOI: 10.1208/s12249-024-03026-y.


Evaluation of the Drug-Drug Interaction Potential of Cannabidiol Against UGT2B7-Mediated Morphine Metabolism Using Physiologically Based Pharmacokinetic Modeling.

Coates S, Bardhi K, Prasad B, Lazarus P Pharmaceutics. 2025; 16(12.

PMID: 39771577 PMC: 11678041. DOI: 10.3390/pharmaceutics16121599.